333 related articles for article (PubMed ID: 23607532)
1. Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease.
Liu C; Xia X; Wu W; Wu R; Tang M; Chen T; Xu F; Cong Y; Xu X; Liu Z
Clin Exp Immunol; 2013 Jul; 173(1):102-11. PubMed ID: 23607532
[TBL] [Abstract][Full Text] [Related]
2. Anti-TNF Therapy Induces CD4+ T-Cell Production of IL-22 and Promotes Epithelial Repairs in Patients With Crohn's Disease.
Fang L; Pang Z; Shu W; Wu W; Sun M; Cong Y; Liu Z
Inflamm Bowel Dis; 2018 Jul; 24(8):1733-1744. PubMed ID: 29718341
[TBL] [Abstract][Full Text] [Related]
3. IL-25 downregulates Th1/Th17 immune response in an IL-10-dependent manner in inflammatory bowel disease.
Su J; Chen T; Ji XY; Liu C; Yadav PK; Wu R; Yang P; Liu Z
Inflamm Bowel Dis; 2013; 19(4):720-8. PubMed ID: 23429464
[TBL] [Abstract][Full Text] [Related]
4. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy.
Caprioli F; Bosè F; Rossi RL; Petti L; Viganò C; Ciafardini C; Raeli L; Basilisco G; Ferrero S; Pagani M; Conte D; Altomare G; Monteleone G; Abrignani S; Reali E
Inflamm Bowel Dis; 2013; 19(4):729-39. PubMed ID: 23448791
[TBL] [Abstract][Full Text] [Related]
5. Increased Th17-inducing activity of CD14+ CD163 low myeloid cells in intestinal lamina propria of patients with Crohn's disease.
Ogino T; Nishimura J; Barman S; Kayama H; Uematsu S; Okuzaki D; Osawa H; Haraguchi N; Uemura M; Hata T; Takemasa I; Mizushima T; Yamamoto H; Takeda K; Doki Y; Mori M
Gastroenterology; 2013 Dec; 145(6):1380-91.e1. PubMed ID: 23993972
[TBL] [Abstract][Full Text] [Related]
6. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
[TBL] [Abstract][Full Text] [Related]
7. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment.
Imaeda H; Bamba S; Takahashi K; Fujimoto T; Ban H; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
J Gastroenterol; 2014 Apr; 49(4):674-82. PubMed ID: 23666424
[TBL] [Abstract][Full Text] [Related]
8. Osteopontin, a protein with cytokine-like properties, is associated with inflammation in Crohn's disease.
Agnholt J; Kelsen J; Schack L; Hvas CL; Dahlerup JF; Sørensen ES
Scand J Immunol; 2007 May; 65(5):453-60. PubMed ID: 17444956
[TBL] [Abstract][Full Text] [Related]
9. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease.
Ricciardelli I; Lindley KJ; Londei M; Quaratino S
Immunology; 2008 Oct; 125(2):178-83. PubMed ID: 18422560
[TBL] [Abstract][Full Text] [Related]
10. Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease.
Liu Z; Yang L; Cui Y; Wang X; Guo C; Huang Z; Kan Q; Liu Z; Liu Y
Inflamm Bowel Dis; 2009 Aug; 15(8):1133-44. PubMed ID: 19322899
[TBL] [Abstract][Full Text] [Related]
11. Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease.
Li J; Ueno A; Fort Gasia M; Luider J; Wang T; Hirota C; Jijon HB; Deane M; Tom M; Chan R; Barkema HW; Beck PL; Kaplan GG; Panaccione R; Qian J; Iacucci M; Gui X; Ghosh S
Inflamm Bowel Dis; 2016 Aug; 22(8):1779-92. PubMed ID: 27243594
[TBL] [Abstract][Full Text] [Related]
12. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease.
Schmitt H; Billmeier U; Dieterich W; Rath T; Sonnewald S; Reid S; Hirschmann S; Hildner K; Waldner MJ; Mudter J; Hartmann A; Grützmann R; Neufert C; Münster T; Neurath MF; Atreya R
Gut; 2019 May; 68(5):814-828. PubMed ID: 29848778
[TBL] [Abstract][Full Text] [Related]
13. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease.
Danese S; Sans M; Scaldaferri F; Sgambato A; Rutella S; Cittadini A; Piqué JM; Panes J; Katz JA; Gasbarrini A; Fiocchi C
J Immunol; 2006 Feb; 176(4):2617-24. PubMed ID: 16456024
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-15 receptor α expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximab.
Perrier C; Arijs I; Staelens D; Breynaert C; Cleynen I; Covens K; Ferrante M; Van Assche G; Vermeire S; de Hertogh G; Schuit F; Rutgeerts P; Ceuppens JL
Immunology; 2013 Jan; 138(1):47-56. PubMed ID: 23039249
[TBL] [Abstract][Full Text] [Related]
15. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis.
Rismo R; Olsen T; Cui G; Christiansen I; Florholmen J; Goll R
Scand J Gastroenterol; 2012 May; 47(5):538-47. PubMed ID: 22486187
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres.
Tursi A; Elisei W; Picchio M; Penna A; Lecca PG; Forti G; Giorgetti G; Faggiani R; Zampaletta C; Pelecca G; Brandimarte G
Eur J Intern Med; 2014 Jun; 25(5):485-90. PubMed ID: 24631020
[TBL] [Abstract][Full Text] [Related]
17. An RORγt Oral Inhibitor Modulates IL-17 Responses in Peripheral Blood and Intestinal Mucosa of Crohn's Disease Patients.
Bassolas-Molina H; Raymond E; Labadia M; Wahle J; Ferrer-Picón E; Panzenbeck M; Zheng J; Harcken C; Hughes R; Turner M; Smith D; Calderón-Gómez E; Esteller M; Carrasco A; Esteve M; Dotti I; Corraliza AM; Masamunt MC; Arajol C; Guardiola J; Ricart E; Nabozny G; Salas A
Front Immunol; 2018; 9():2307. PubMed ID: 30405600
[No Abstract] [Full Text] [Related]
18. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease.
Sugita S; Kawazoe Y; Imai A; Yamada Y; Horie S; Mochizuki M
Arthritis Res Ther; 2012 May; 14(3):R99. PubMed ID: 22546542
[TBL] [Abstract][Full Text] [Related]
19. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
[TBL] [Abstract][Full Text] [Related]
20. Profile of soluble cytokine receptors in Crohn's disease.
Gustot T; Lemmers A; Louis E; Nicaise C; Quertinmont E; Belaiche J; Roland S; Van Gossum A; Devière J; Franchimont D
Gut; 2005 Apr; 54(4):488-95. PubMed ID: 15753533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
